Opening new pathways
for chronic total occlusion
recanalization
INNOVATIVE 2-IN-1 TECHNOLOGY
A built-in scaffold that supports the guidewire and tip and enables effective and precise crossing of the lesion
An integrated microcatheter that follows the guidewire into the lesion and assists in opening the blockage
Nitiloop’s innovative technology enables superior chronic total occlusion (CTO) revascularization. It uniquely combines a scaffold that provides stable distal support to a standard 0.014" guidewire, with an intra-lumen crosser microcatheter. The technology has been clinically proven to deliver high antegrade procedure success rates with low perforation rates. Nitiloop’s advanced solution enables even relatively new CTO practitioners at low-volume clinics to perform antegrade CTO procedures safely and successfully.
HOW IT WORKS
NovaCross™ Xtreme Animation
NovaCross™ Xtreme vs. Competitor
NITILOOP'S PRODUCT LINE
NovaCross™
Coronary and peripheral applications
For difficult to treat coronary and peripheral lesions
Coronary and peripheral applications
For very challenging coronary and peripheral CTO procedures
Peripheral applications
Below-the-Knee
For challenging lesions in the peripheral vasculature
NovaCross™ Xtreme
NovaCross™ BTK
CLINICAL MILESTONES
Nitiloop completed a pivotal clinical study that assessed the safety and efficacy of the NovaCross™ device for revascularization of coronary CTO. The study included 186 patients in 10 centers in the U.S., Europe and Israel.
STUDY HIGHLIGHTS
-
High efficacy: 76%
-
Antegrade technical success: 88%
-
Technical success rate: 75.3%
-
Safety Results (MACE)
- Death: 0%
- Device related perforation: 2.2%
- Bypass surgery: 0%
- MI ≤ 12.3 % (CKMB>3ULN)
Based on the study, the NovaCross™ received FDA clearance
for treating CTO prior to PTCA or Stent Intervention.
Dr. William Nicholson
Wellspan Hospital
York, PA, USA
The NovaCross™ is a significant new addition to our CTO toolbox for tackling lesions. It improves our antegrade success rate while minimizing the risk of perforation. The device is simple and safe and can be easily adopted by either high-volume or low-volume cath lab clinicians.
Dr. Simon Walsh
Belfast Trust Hospital
United Kingdom
The NovaCross™ device has now completed evaluation in first-in-human and a pivotal FDA approval trial. The data confirms that the device is safe and efficacious, facilitating proximal cap crossing and success with antegrade wiring in complex lesions. The NovaCross™ gives added support for wiring and does not require added training for physician use.
ABOUT
Nitiloop is an Israeli startup company founded by Professor Ran Kornowski, a world-renowned cardiologist and opinion leader and Dvir Keren, a serial entrepreneur specializing in health innovation.
The company has developed innovative devices that facilitate successful antegrade CTO coronary and peripheral procedures.
Nitiloop’s solutions enable the company to tap into the $500M CTO market. Nitiloop is backed by prominent investors that include Accelmed Ventures, Access Medical Ventures, Arkin Holdings and Tal Capital.
